<DOC>
	<DOCNO>NCT01185730</DOCNO>
	<brief_summary>The objective clinical research analyze survival cohort patient newly diagnose ( incident case ) idiopathic PAH , familial associate use anorectic ( isolated pulmonary vascular disease without comorbidity ) identify prognostic factor use dynamic model predict survival , include prognostic factor evaluate repeatedly pre-specified period follow-up . In second step , investigator define use model combination parameter well define therapeutic goal PAH ( functional class , exercise testing , hemodynamic , echocardiographic variable , biological parameter ) .</brief_summary>
	<brief_title>Prospective Longitudinal Study Patients With Idiopathic Pulmonary Arterial Hypertension , Family Taking Anorectics</brief_title>
	<detailed_description>Pulmonary arterial hypertension ( PAH ) rare disease characterize intense proliferation pulmonary arterial wall causing increase progressive pulmonary vascular resistance , lead right heart failure death . Established prognostic factor diagnosis identify 20 year ago time specific treatment describe natural history disease . Over last 10 year , new therapeutic class ( similar prostacyclin , antagonists endothelin receptor , inhibitor phosphodiesterase 5 ) develop improve symptom , exercise capacity , hemodynamics patient PAH . With availability new molecule , clinician face difficult treatment decision regard choice initial treatment need road treatment combine evolution . Therapeutic purpose effect different therapeutic strategy long-term survival remain poorly understood . If clearly demonstrate clinical parameter ( NYHA functional class ) , functional ( test 6-minute walk ) hemodynamic ( cardiac output pulmonary vascular resistance ) measure initiation treatment major role determine prognosis , contribution new molecule important evaluate prognostic value change factor follow-up specific treatment . At baseline assessment , include repeat cardiac catheterization right , also important evaluate prognostic criterion substitution , include method noninvasive evaluation ( echocardiography , biomarkers ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Inclusion criterion : Man woman age 18 year With pulmonary arterial hypertension ( PAH ) idiopathic , hereditary associate use anorectic , newly diagnose ( less 6 month ) whose diagnosis make cardiac catheterization find mean pulmonary arterial pressure ( mPAP ) &gt; 25 mm Hg rest &gt; 30 mm Hg exercise , pressure pulmonary artery occlusion ( PAOP ) â‰¤ 15 mm Hg , Has give free informed consent . Exclusion criterion : Minor ( age &lt; 18 year ) PAH patient whose diagnosis 6 month ( prevalent case ) , Patient PAH associate concomitant disease ( autoimmune disease , portal hypertension , HIV infection , congenital heart disease , schistosomiasis , chronic hemolytic anemia ) Patient venoocclusive disease / pulmonary capillary hemangiomatosis suspect documented Patients pulmonary hypertension associate left heart ( pulmonary hypertension postcapillary ) Patients pulmonary hypertension associate respiratory disease ( chronic obstructive pulmonary disease , pulmonary fibrosis , sleep apnea syndrome Sleep ) Patients pulmonary hypertension postembolic chronic Patient pulmonary hypertension associate sarcoidosis , histiocytosis X , Lymphangioleiomyomatosis mediastinal fibrosis , Adults protect Pregnant lactate Persons deprive liberty Persons emergency situation , Persons refuse unable give inform consent . No affiliation social security scheme ( beneficiary beneficiary )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Prognostic factor</keyword>
	<keyword>Idiopathic pulmonary hypertension</keyword>
	<keyword>Family pulmonary hypertension</keyword>
	<keyword>use anorectic</keyword>
</DOC>